ArticleAsian Pacific journal of cancer prevention : APJCP2026
Synthesis of Immunotoxin of Anti-CD3 Monoclonal Antibody-Bongkrekic Acid and Cytotoxic Effect Against CD3+ T Cells in Peripheral Blood Mononuclear Cells.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer is a major health concern worldwide. Common cancer treatments such as surgery, chemotherapy, and radiotherapy have not been able to completely reduce the rate of cancer-related death. Monoclonal antibodies (MAb) have been widely used for cancer treatment in the form of immunotherapy or targeted therapy. Immunotoxins are a form of targeted therapy based on monoclonal antibody-toxin conjugates. Antibodies deliver toxins to specific cancer cells and induce cell death.
objectiveThis study aimed to synthesize a conjugate of bongkrekic acid (BKA), a potent mitochondrial toxin, with anti-CD3 MAb and evaluate its specificity in peripheral blood mononuclear cells (PBMC).
methodsIn silico assays were performed to predict conjugation sites and interactions between BKA and MAb. The synthesis of the conjugate was carried out chemically using EDC-HCl/Sulfo-NHS zero-length crosslinker and confirmed using a UV-Vis spectrophotometer. PBMC were used as a specificity test model. The conjugate exhibited selective cytotoxic toward CD3+ T cells without affecting other cells in PBMCs.
resultsIn silico assays using molecular docking showed conjugation sites in the cavity of the CH2-CH3 Fc IgG2a domain and covalent interactions with lysine, asparagine, and glutamine amino acids. Measurements of absorption at wavelengths of 280 and 260 nm indicated the presence of protein and BKA in the synthesized conjugate. Incubation of PBMC with BKA and anti-CD3 MAb resulted in a significantly lower average number of cells (p< 0.05) than that observed in the group treated with the conjugate.
conclusionIn silico assays revealed an interaction between the carboxylic groups of BKA and the primary amine group of antibodies. The Conjugates exhibited lower cytotoxicity compared to BKA and anti-CD3 Mab individually. In vitro assays have not been able to show the specificity of the conjugate due to the anti-CD3 MAb alone exhibiting cytotoxic properties in PBMCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.